Overview

STREAMER : STent Restenosis And MEdicaments Release

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
0
Participant gender:
All
Summary
It is a pilot study to evaluate the feasibility and the efficiency of local delivery of paclitaxel after stenting of long femoropopliteal arterial lesions TASC C and D before the realization of a large randomized multicentric study. Patients concerned are in critical ischemia.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hospices Civils de Lyon
Treatments:
Albumin-Bound Paclitaxel
Paclitaxel
Criteria
Inclusion Criteria:

- patients with critical ischemia of a lower limb with ankle pressure < 50 mmHg

- lesions TASC C and D of the superficial femoral or popliteal artery

Exclusion Criteria:

- patient allergic to paclitaxel

- patient with a cancer, a neutropenia, with immunosuppressor medicament or chemotherapy

- patient with contraindication to take 2 anti-aggregants platelets